About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

0.5766 -0.0796 (-12.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,008,616
Open 0.6665
Bid (Size) 0.5810 (1)
Ask (Size) 0.6000 (3)
Prev. Close 0.6562
Today's Range 0.5766 - 0.6700
52wk Range 0.5300 - 5.620
Shares Outstanding 40,743,762
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BTAI Stock Earnings: BioXcel Therapeutics Beats EPS, Beats Revenue for Q2 2024
BTAI stock results show that BioXcel Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrated favorable safety and efficacy in reducing agitation symptoms. 
Via Benzinga

Performance

YTD
-80.32%
-80.32%
1 Month
-13.75%
-13.75%
3 Month
-49.42%
-49.42%
6 Month
-79.63%
-79.63%
1 Year
-80.91%
-80.91%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
BioXcel Therapeutics's Earnings Outlook
Via Benzinga
Why BioXcel Therapeutics Shares Are Falling Today
Via Benzinga
AI Surge Has Ended: All 7 AI Stock Categories Declined This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
Earnings Scheduled For March 12, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Leading The Charge: Tonix Pharmaceuticals And The Future Of CNS Therapeutics
Via Get News
Why BioXcel Therapeutics Shares Are Rising Tuesday
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is CleanSpark (CLSK) Stock Up 27% Today?
Via InvestorPlace
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.